RTP Mobile Logo
Submitted by web@researchtop... on Mon, 10/08/2018 - 15:13
LCU218

Interview with Geoffrey R Oxnard, MD

Track 1: Use of liquid biopsies in patients with lung cancer
Track 2: Benefits and limitations of liquid biopsies
Track 3: First-line therapy for patients with metastatic non-small cell lung cancer (NSCLC) with EGFR tumor mutations
Track 4: Case: A man in his sixties, a nonsmoker, with NSCLC, an EGFR tumor mutation and brain metastases receives first-line osimertinib
Track 5: Management of brain metastases in patients with NSCLC and EGFR tumor mutations
Track 6: Results of the Phase III ARCHER 1050 trial evaluating dacomitinib versus gefitinib as first-line therapy for NSCLC with EGFR-activating mutations
Track 7: Investigational treatment strategies for patients experiencing disease progression on osimertinib
Track 8: Role of checkpoint inhibitors for patients with NSCLC and targetable tumor mutations
Track 9: Potential combination of EGFR tyrosine kinase inhibitors with other targeted agents
Track 10: Status of the Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials (ALCHEMIST) for patients with early-stage disease
Track 11: Clinical experience with the use of EGFR and ALK inhibitors in the adjuvant setting
Track 12: Case: A 55-year-old man and never smoker with heavily pretreated metastatic NSCLC with an ALK rearrangement
Track 13: Activity and tolerability of the next-generation ALK inhibitors
Track 14: Management of ALK inhibitor-resistant disease
Track 15: Case: A 47-year-old man and never smoker with newly diagnosed metastatic nonsquamous NSCLC with a RET rearrangement and a high PD-L1 tumor proportion score
Track 16: Efficacy and tolerability of the highly selective RET inhibitor LOXO-292 for patients with cancers with RET alterations
Track 17: Case: A 51-year-old woman and never smoker with metastatic nonsquamous NSCLC with a MET amplification experiences a prolonged response to crizotinib
Track 18: Investigation of the tropomyosin receptor kinase (TRK) inhibitors entrectinib and larotrectinib for adult and pediatric patients with cancers harboring a TRK fusion
Track 19: Case: A 74-year-old woman and never smoker with metastatic nonsquamous NSCLC and a BRAF V600E tumor mutation receives dabrafenib/trametinib
Track 20: Choosing between first-line anti-PD-1/PD-L1 monotherapy and an anti-PD-1/PD-L1 inhibitor in combination with chemotherapy for metastatic lung cancer
Track 21: Mechanism of action and efficacy of the antibody-drug conjugate rovalpituzumab tesirine (Rova-T) in DLL3-expressing recurrent small cell lung cancer (SCLC)
Track 22: Role of ipilimumab/nivolumab as therapy for metastatic lung cancer
Track 23: Management of pulmonary toxicity in patients receiving immune checkpoint inhibitors

Interview with Martin Reck, MD, PhD

Track 1: Efficacy of immune checkpoint inhibitors in patients with metastatic NSCLC
Track 2: Combination immunotherapy approaches under investigation for NSCLC
Track 3: Response to anti-PD-1/PD-L1 antibodies in patients with targetable tumor mutations
Track 4: PD-L1 expression and tumor mutation burden as predictors of response to checkpoint inhibitors
Track 5: Approach to the treatment of nonsquamous NSCLC in patients without a targetable tumor mutation
Track 6: Therapeutic options for patients with metastatic squamous cell NSCLC
Track 7: Results of the Phase III CheckMate 227 trial of nivolumab with ipilimumab as first-line therapy for patients with advanced NSCLC and a high tumor mutation burden
Track 8: PACIFIC trial: Efficacy and tolerability of durvalumab after chemoradiation therapy for unresectable Stage III NSCLC
Track 9: Perspectives on the potential synergy between durvalumab and chemoradiation therapy in the PACIFIC trial
Track 10: Integration of durvalumab into the therapeutic algorithm for NSCLC
Track 11: Case: A 69-year-old man with advanced mesothelioma receives pembrolizumab after disease progression on chemotherapy
Track 12: Activity and tolerability of pembrolizumab in patients with mesothelioma
Track 13: Case: A 63-year-old woman with metastatic NSCLC, polymyalgia rheumatica and temporal arteritis experiences a dramatic response to pembrolizumab
Track 14: Use of immune checkpoint inhibitors for patients with preexisting autoimmune disease
Track 15: Case: A 61-year-old man with metastatic SCLC receives platinum-based chemotherapy followed by nivolumab/ipilimumab maintenance therapy on the CheckMate 451 trial
Track 16: Case: A 61-year-old woman with metastatic nonsquamous NSCLC receives carboplatin/pemetrexed/pembrolizumab followed by maintenance pembrolizumab/pemetrexed on the KEYNOTE-189 trial
 
FACULTY
 
Geoffrey R Oxnard, MD
Lowe Center for Thoracic Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts
 
Martin Reck, MD, PhD
Head of Department of
Thoracic Oncology
Head of Clinical Trial Department
LungenClinic Grosshansdorf
Grosshansdorf, Germany
 
EDITOR
 
Neil Love, MD
Research To Practice
Miami, Florida